ANXA1 and colorectal carcinoma: Additionally, elucidation of the downstream ANXA1 effectors in treatment-resistant tumor cells and elucidation of its interactions with other pathways of therapy resistance could set the development of novel strategies to overcome CRC chemoresistance, which are mainly registered in locally advanced tumors.